Objective: To assess whether single nucleotide polymorphisms of HSD17B5 (AKR1C3) (rs1937845 and rs12529) and HSD17B6 (rs898611) are associated with polycystic ovary syndrome (PCOS) in a Chinese population. Design: A case-control study was conducted to investigate the relation between HSD17B5 and HSD17B6 polymorphisms and PCOS. Methods: In this study, 335 patients with PCOS and 354 controls were recruited. The genotypes of HSD17B5 (rs1937845 and rs12529) and HSD17B6 (rs898611) were detected by the TaqMan method. Results and conclusions: We found that the genotypic frequencies of the rs1937845 polymorphism were different in subjects with PCOS compared with control, with the CT genotype being more commonly found in patients with PCOS than in controls (PZ0.005). We observed a significantly 1.74-fold higher risk of CT genotype in the polymorphism rs1937845 in women with PCOS vs the control group (adjusted odds ratio (OR), 1.74; 95% CIZ1.19-2.54; PZ0.005). A similar, significant 1.47-fold higher risk (adjusted OR, 1.47; 95% CIZ1.07-2.03; PZ0.018) was demonstrated for T allele of polymorphism rs1937845 associated with PCOS. In patients with PCOS, the rs12529 (GOC) and rs1937845 (COT) polymorphisms were strongly associated with the high level of testosterone. The TT carriers of polymorphism rs1937845 had a significantly increased homeostatic model assessment-B% (HOMA-B%) (PZ0.045) and that might be associated with the high risk of insulin resistance. However, no significant difference was found in genotype or allele distributions of the polymorphisms rs12529 of HSD17B5 and rs898611 of HSD17B6 between patients with PCOS and controls. Additionally, the two polymorphisms of HSD17B5 are associated with hyperandrogenemia in patients with PCOS. In conclusion, our findings showed a significant statistical association between HSD17B5 rs1937845 and PCOS risk in Chinese women. The CT genotype and T allele frequency are influenced significantly to a higher extent in patients with PCOS than controls. Further studies are needed to confirm the results and find out the exact molecular mechanism of the polymorphism on the risk of hyperandrogenemia and PCOS.
Introduction
Polycystic ovary syndrome (PCOS) is a most common endocrine disorder affecting 7.4% of Chinese women of childbearing age (1, 2) . In addition to irregular menstruation, the phenotypes of this endocrine disorder also include hyperandrogenemia, high levels of estrone and insulin, high ratio of luteinizing hormone (LH)/folliclestimulating hormone (FSH) and dyslipidemia. Heredity and environmental changes have been considered to be the causative factors for PCOS (3, 4) . According to Rotterdam criteria in 2003 (5) , the characteristics of PCOS are chronic anovulation and/or oligomenorrhea, clinical and/or biochemical hyperandrogenemia, and polycystic ovary morphology (6) . These clinical features suggest that multiple genes are involved in the pathology of PCOS, such as genes regulating steroid hormones functions and insulin resistance (2, 7) . One study suggested a genetic basis for the hyperandrogenemia of PCOS was found in the family members of PCOS probands, with increased rates of hyperandrogenemia with and without PCOS (8) . Therefore, research on polymorphisms of genes related to androgen biosynthesis and metabolism has long been focused on (9) . Several genes have already been reported to be associated with hyperandrogenism and PCOS. Most of these candidate genes could affect the synthesis, action, and regulation of androgen, such as CYP11A1, CYP17 (CYP17A1), CYP19 (CYP19A1), AR and 17b-hydroxysteroid dehydrogenase (HSD17B) (9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20) .
HSD17B5 (AKR1C3), located at chromosome 10p15-p14, is a member of the aldo-keto reductase superfamily comprising several multifunctional enzymes that differ between their tissue-specific expression profiles and their substrate specializations (9) . HSD17B5 encodes the enzyme responsible for reduction of androstenedione to testosterone in theca ovarian cells and adrenals, which are the main sources of testosterone in women (9, 16) . It is a candidate gene to be analyzed for the hyperandrogenemia in PCOS. HSD17B6 is located at chromosome 12q13. It plays an important role in regulating the equilibrium of active androgen available for androgen receptor by catalyzing the production of potent androgens such as 5a-dihydrotestosterone from 3a-androstanediol (17) . Protein encoded by this gene has both oxidoreductase and epimerase activities and is involved in androgen catabolism. It has been reported that HSD17B6 plays an important role in the development of PCOS (18) . A previous genetic study reported a significant association between polymorphism rs898611 in HSD17B6 and PCOS (20) . In that case-control study, using DNA samples from 173 patients with PCOS and 107 normally ovulating women of Caucasian descent from the general community, the authors found that the polymorphic allele of rs898611 in HSD17B6 was associated with a reduced fasting glucose-insulin ratio (GIR), reduced testosterone, and an increased BMI and homeostasis model assessment of insulin resistance (HOMA-IR) (20) .
In this study, we aimed to evaluate the polymorphisms rs12529 and rs1937845 of HSD17B5 and rs898611 of HSD17B6 in an independent population and tried to provide evidence for the association of these polymorphisms with PCOS in Chinese women.
Subjects and methods

Study population
In this study, a total of 689 subjects were enrolled from Jiangsu Province Hospital Affiliated to Nanjing Medical University and Nanjing Maternity and Child Healthcare Hospital between March 2005 and February 2009, including 335 patients with PCOS and 354 healthy subjects. Patients with PCOS (mean age: 28.04G3.87 years) were from those who routinely referred to our outpatient clinic for PCOS evaluation. Patients with PCOS were selected according to the Rotterdam criteria (5) and did not have a history of fertility. All subjects were non-smokers and normotensive.
The diagnosis of PCOS was based on the Rotterdam criteria 2003. According to these criteria, two out of three of the following were required to be present so as to confirm PCOS: oligo-ovulation or oligomenorrhea, clinical or biochemical hyperandrogenemia, and polycystic ovary morphology (5) . Patients with other endocrine diseases related to reproduction such as Cushing's syndrome, androgen-secreting tumors, hyperprolactinemia and congenital adrenal hyperplasia were excluded after special laboratory analyses. Oligo-ovulation was determined by menstrual cycle longer than 35 days or !26 days. Hyperandrogenemia was determined by the clinical presence of hirsutism (Ferriman-Gallwey score R6), acne and/or alopecia, and/or high androgen (normal range: total testosterone 0.1-0.75 ng/ml). Polycystic ovaries were determined using ultrasound by the presence of 12 or more small (2-9 mm in diameter) follicles in each ovary and/or increased ovarian volume (O10 ml; calculated by 0.5 length!width!thickness) (5) . Controls were fertile women (nZ354, mean age: 30.15G3.08 years) with regular menstrual cycles and no evidence of hirsutism, acne, alopecia, or endocrine dysfunction. All subjects belonged to non-relative Chinese Han ethnic group. This study was approved by the Institutional Ethics Committee of Nanjing Medical University. A signed informed consent was obtained from each subject.
Sample collection
Heparinized whole-blood samples were collected in the morning after fasting overnight during day 3 to day 5 of a spontaneous menstrual cycle or a progesterone-induced withdrawal bleeding from patients with PCOS using tubes containing EDTA (as anticoagulant). Genomic DNA was extracted from the peripheral blood leukocytes using standard phenol-chloroform method. On the day of blood drawing, each subject had a physical examination including weight, height, waist, and hip circumference measurement. FSH, LH, prolactin (PRL), testosterone, and estradiol (E 2 ) were determined by chemiluminescence assay. The following formulas were used to calculate some parameters: HOMA-B%Z20!fasting insulin/ (fasting glucoseK3.5). HOMA-IRZfasting insulin!fasting glucose/22.5 (normal range: !1.8). QUICKIZ1/(logFINS ClogFPG (mg/dl)) (normal range: R0.375). BMIZweight (kg)/height 2 (m 2 ) (normal range: 18-25).
Genotyping
Genetic variants of HSD17B5 and HSD17B6 were investigated based on the HapMap database (http://www. hapmap.org). According to the criteria (minimum allele frequency (MAF) R10% and r 2 R0.8), two polymorphisms rs12529 (intron) and rs1937845 (5 0 UTR) of HSD17B5 and one polymorphism rs898611 (intron) of HSD17B6 were selected. Genotypes were detected by the TaqMan allelic discrimination Assay on an ABI 7900HT Fast realtime PCR system (Applied Biosystems). For the quality control, all the genotyping assays were performed without knowing whether it was from the case/control status and a random 5% of cases and controls were genotyped twice by another technician, yielding 100% concordance.
Statistical analysis
Fluorescence data were exported into Excel format and analyzed as scatter points. The Hardy-Weinberg equilibrium (HWE) was tested by a goodness-of-fit c 2 test. The allele frequency and genotype distribution differences between patients with PCOS and controls were analyzed by c 2 test. The general clinical and metabolic variables of patients with PCOS were expressed as meanGS.D. The risk of PCOS was estimated as odds ratios (ORs) and 95% CI using unconditional multivariate logistic regression adjusted for age and BMI. All statistical analyses were performed using Stata (Version 9.0, StataCorp LP, College Station, TX, USA), and P!0.05 were considered to be significant.
Results
The characteristics of patients are shown in Table 1 . The levels of LH, testosterone, and HOMA-IR were higher and QUICKI was lower in patients with PCOS. Other parameters were within the normal range ( Table 1) .
The crude genotype frequencies and main effect model in patients with PCOS and controls for each polymorphism are summarized in Table 2 . The frequencies for patients with PCOS were in the HWE; PZ0.853 for rs12529, PZ0.957 for rs1937845, and PZ0.404 for rs898611. The genotype frequencies of the two polymorphisms (rs12529 and rs898611) in the control group were in accordance with the HWE expectations (PZ0.949 for rs12529 and PZ0.268 for rs898611), while the rs1937845 genotype distribution was not in conformity with the HWE in the control group (PZ0.006). Compared with CC homozygotes, subjects carrying CT homozygote had an increased risk of being PCOS after adjusting for potential covariates (age and BMI) (adjusted OR, 1.74; 95% CIZ1.19-2.54; PZ0.005). In addition, the subjects (Table 2) . Additionally, no significant difference was found in the genotype frequencies of the polymorphisms HSD17B5 rs12529 and HSD17B6 rs898611 between patients with PCOS and controls ( Table 2) . The relationship between the HSD17B5 and HSD17B6 polymorphisms and clinical phenotypes are shown in Supplementary Tables S1 and S2, see section on supplementary data given at the end of this article. As shown in Supplementary Table S2 , the level of HOMA-B% were significantly higher in patients with PCOS carrying rs1937845 TT genotype than that in patients with CC genotype (PZ0.045). The levels of testosterone were also much higher in patients with PCOS with TT genotype, but did not reach the statistically significant level (PZ0.053). Patients with CC genotype of rs12529 had a much higher level of testosterone than those carrying GG genotype (PZ0.034). However, no significant association was found between clinical characteristics and polymorphism rs898611 in HSD17B6 ( Supplementary Table S1 ).
In order to investigate the relationship between the three polymorphisms and hyperandrogenemia, we divided patients with PCOS into two subgroups: hyperandrogenemia and without hyperandrogenemia.
Significantly higher levels of BMI (PZ0.014) and E 2 (PZ0.009) were found in the subgroup of hyperandrogenemia ( Supplementary Table S3 , see section on supplementary data given at the end of this article). As shown in Table 3 , the genotype distribution of rs12529 and rs1937845 were significantly different between the two subgroups. The C allele of polymorphism rs12529 was significantly associated with the risk of hyperandrogenism (OR, 2.38; 95% CI, 1.36-4.17; PZ0.002). Additionally, the CT genotype and T allele in rs1937845 had a higher frequency in the hyperandrogenism group (PZ0.007 and 0.004 respectively). However, no significant association was found between the genotypes of rs898611 and hyperandrogenism.
Discussion
The incidence of PCOS has gradually increased during recent years with the changes in living environment and the increases in social pressure (21) . Among the complex clinical features, hyperandrogenism is a typical clinical manifestation of a patient with PCOS (22) . Hyperandrogenism can cause follicular atresia, anovulation, menstrual disorders and infertility. Moreover, it can lead to acne, hairy and greasy skin, hair loss and other clinical symptoms.
PCOS is a hereditary endocrine disorder in young women, which is well known. Polymorphisms are common DNA sequence variations among population that play important roles in the development of several hereditary diseases. HSD17B5 and HSD17B6 are key genes in androgenic metabolism (9) . We observed a significantly higher risk of CT genotype and T allele in the polymorphism rs1937845 in women with PCOS vs the control group. However, no significantly different distribution of genotypes or allele of polymorphism rs898611 was observed between patients with PCOS and controls. In addition, we examined the association between the polymorphisms of HSD17B5 and HSD17B6 and the clinical features of PCOS. In contrast to the findings of a previous study in which it has been found that a polymorphic allele of polymorphism rs898611 was associated with PCOS and key phenotypic features of PCOS (20), we did not find any significant association between genotypes or polymorphic allele of rs898611 and phenotypic features of PCOS. The inconsistency might be due to several reasons. First, it may be due to different genetic backgrounds, which cause ethnic differences in association studies. In our studies, we found that the frequency of C allele was lower in Asians than in Caucasians. Secondly, the sample size in this study is larger and is more likely to find the real association. Thirdly, in multifactorial diseases like PCOS, not only genetic factors, but also environmental risk factors play important roles (23) . We speculated that the difference might also be attributed by environmental factors. After dividing patients with PCOS into two subgroups based on their testosterone level, we found that patients in the hyperandrogenism group had a higher BMI and E 2 . The result indicated that obese subjects were prone to have high testosterone levels. As testosterone is the substrate of E 2 , high testosterone levels might result from high E 2 levels. Then, we evaluated the distribution of the genotypes between the two subgroups with metabolic variants and anthropometric characteristics. Compared with CC genotype, the TT genotype of rs1937845 had a higher level of HOMA-B% and testosterone, indicating that T allele of rs1937845 conferred risk to insulin resistance and was associated with hyperandrogenism. We also found a significant difference in testosterone levels between CC and GG genotypes of rs12529. The GOC in rs12529 might confer a higher risk to hyperandrogenism. These results provide evidences that GOC of rs12529 and COT of rs1927845 might be associated with hyperandrogenism in patients with PCOS. The rs12529 and rs1937845 of HSD17B5 may participate in regulation of the metabolism of hyperandrogenism in patients with PCOS. Furthermore, in this study, the genotypes of rs898611 did not show any association with clinic characteristics of PCOS, which is consistent with the results of a previous association study carried out with samples of the Chinese population (24) .
In this study, the distribution of rs1937845 genotype was in accordance with HWE in the patient group, but not in the control group. However, we could not explain the reason for this in the controls. We have ruled out the possibility of incorrect genotyping of the polymorphism. We speculated that the polymorphism is a new susceptibility locus for PCOS in the Chinese population. The association of the polymorphism rs1937845 with PCOS needs further confirmation with a larger sample size.
In conclusion, our study suggested that the two polymorphisms of HSD17B5 may play certain roles in the occurrence of hyperandrogenemia in patients with PCOS and may be associated with insulin resistance. HSD17B5 may be regarded as a candidate gene for the etiopathogenesis of PCOS. Although it is not known at present as to how polymorphisms in the HSD17B5 lead to different metabolic parameters, it is possible that the variation of the sequence might alter the expression or the function of the signal pathways and lead to hyperandrogenism and insulin resistance. Our findings still need to be further confirmed by larger sample size studies with a different ethnicity. Future studies are required to find out the exact molecular mechanism of the polymorphism on the risk of hyperandrogenemia and PCOS.
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